AU2002316081B2 - Prostanoic acid derivatives as agents for lowering intraocular pressure - Google Patents

Prostanoic acid derivatives as agents for lowering intraocular pressure Download PDF

Info

Publication number
AU2002316081B2
AU2002316081B2 AU2002316081A AU2002316081A AU2002316081B2 AU 2002316081 B2 AU2002316081 B2 AU 2002316081B2 AU 2002316081 A AU2002316081 A AU 2002316081A AU 2002316081 A AU2002316081 A AU 2002316081A AU 2002316081 B2 AU2002316081 B2 AU 2002316081B2
Authority
AU
Australia
Prior art keywords
hydroxy
enoic acid
hydroxypent
enyl
hept
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002316081A
Other languages
English (en)
Other versions
AU2002316081A1 (en
Inventor
Robert M. Burk
Todd S. Gac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2002316081A1 publication Critical patent/AU2002316081A1/en
Application granted granted Critical
Publication of AU2002316081B2 publication Critical patent/AU2002316081B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002316081A 2001-05-17 2002-05-07 Prostanoic acid derivatives as agents for lowering intraocular pressure Ceased AU2002316081B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/859,770 2001-05-17
US09/859,770 US6531504B2 (en) 2001-05-17 2001-05-17 Prostanoic acid derivatives as agents for lowering intraocular pressure
PCT/US2002/014580 WO2002092099A1 (en) 2001-05-17 2002-05-07 Prostanoic acid derivatives as agents for lowering intraocular pressure

Publications (2)

Publication Number Publication Date
AU2002316081A1 AU2002316081A1 (en) 2003-05-01
AU2002316081B2 true AU2002316081B2 (en) 2007-11-15

Family

ID=25331661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002316081A Ceased AU2002316081B2 (en) 2001-05-17 2002-05-07 Prostanoic acid derivatives as agents for lowering intraocular pressure

Country Status (9)

Country Link
US (2) US6531504B2 (OSRAM)
EP (1) EP1390036B1 (OSRAM)
JP (1) JP4606698B2 (OSRAM)
AT (1) ATE548042T1 (OSRAM)
AU (1) AU2002316081B2 (OSRAM)
CA (1) CA2446994C (OSRAM)
DK (1) DK1390036T3 (OSRAM)
ES (1) ES2381340T3 (OSRAM)
WO (1) WO2002092099A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
CA2515631C (en) * 2003-02-11 2013-08-20 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7186744B2 (en) * 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US8648213B2 (en) 2004-10-06 2014-02-11 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2009065081A2 (en) * 2007-11-14 2009-05-22 Cayman Chemical Company Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US20110020453A1 (en) * 2009-02-06 2011-01-27 Steven Blum Topical Formulations Comprising Ion Channel Modulators
KR101045935B1 (ko) 2009-03-11 2011-07-01 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096902A (en) * 1996-02-29 2000-08-01 Allergan Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO2000051980A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US6204287B1 (en) * 1992-09-21 2001-03-20 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE37602B1 (en) * 1971-05-11 1977-08-31 Ici Ltd Cyclopentane derivatives
AR204816A1 (es) * 1972-11-08 1976-03-05 Pfizer Procedimiento para preparar una prostaglandina
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
DE69311361T2 (de) * 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
SE9702706D0 (sv) * 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
HUP0004436A3 (en) * 1997-09-09 2001-09-28 Procter & Gamble Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204287B1 (en) * 1992-09-21 2001-03-20 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6096902A (en) * 1996-02-29 2000-08-01 Allergan Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO2000051980A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs

Also Published As

Publication number Publication date
US6670485B2 (en) 2003-12-30
CA2446994C (en) 2011-02-01
ES2381340T3 (es) 2012-05-25
US20020177620A1 (en) 2002-11-28
EP1390036B1 (en) 2012-03-07
EP1390036A1 (en) 2004-02-25
ATE548042T1 (de) 2012-03-15
US6531504B2 (en) 2003-03-11
US20030105155A1 (en) 2003-06-05
DK1390036T3 (da) 2012-04-10
WO2002092099A1 (en) 2002-11-21
JP2004530687A (ja) 2004-10-07
JP4606698B2 (ja) 2011-01-05
CA2446994A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP0789687B1 (en) Ep2-receptor agonists as agents for lowering intraocular pressure
US6410591B1 (en) 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
WO1993014743A2 (en) Polar c-1 esters of prostaglandins
US6767920B2 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
AU2002305416A1 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
CA2446994C (en) Prostanoic acid derivatives as agents for lowering intraocular pressure
AU2002316081A1 (en) Prostanoic acid derivatives as agents for lowering intraocular pressure
IE913906A1 (en) 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular¹hypotensives
US6706755B2 (en) Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US6258844B1 (en) Cyclopentane (ene) oic acid, 2-alkenyl derivatives as therapeutic agents
US6812240B1 (en) 8-azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
EP0562016B1 (en) 2-decarboxyl-2-alkoxyalkyl prostaglandins as ocular hypotensives
US5656635A (en) 5-trans-alcohols and their use as ocular hypotensives
IE920397A1 (en) 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
AU2002314975A1 (en) Cyclopentane heptan (ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired